Thought Leadership
340B Orphan Drug News You Can Use
Expert insights by Dr. Lisa Nezneski, PharmD, BCPS — for rural and community hospitals navigating orphan drug exclusions, rebate models, and policy changes.
Critical Analysis: CBO's September 2025 Report on the 340B (Orphan) Drug Pricing Program
340B Rebate Model and the Orphan Drug Exclusion: A Critical Gap in Coverage
Trump's Drug Price Executive Orders: A 340B Orphan Drug Perspective
Hospitals Are Losing $200K+ Every Year ...And Most Don't Even Know It
Be honest. What's the one 340B problem keeping you up at night?
Webinar Recap: The $450,000 Case Study (And What It Means For You)
340B Coalition Conference Highlights for Expansion Entities
Two Courts. Forty-Five Days. Doors That Just Opened for Your Facility.
Washington Is Talking About Your Orphan Drug Revenue — Are You Capturing It?
Sign up now to get the latest news and strategies in your email.
SUBSCRIBE NOW →No spam. Unsubscribe anytime.
Maximizing savings. Ensuring compliance. Advancing access to life-changing therapies.
© 2026 340B Orphan Drug Solutions. All rights reserved.